INNA-051

ENA Respiratory Pty Ltd · Phase 2 active Small molecule

At a glance

Generic name	INNA-051
Sponsor	ENA Respiratory Pty Ltd
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age (PHASE2)
INNA-051 Influenza Challenge Study (PHASE2)
Intranasal INNA-051 for Prevention of COVID-19 in Adults (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

INNA-051 CI brief — competitive landscape report
INNA-051 updates RSS · CI watch RSS
ENA Respiratory Pty Ltd portfolio CI